- Trial phase
- IND cleared / preclinical
- Time to market
- Early preclinical/IND-stage; if clinical trials begin soon, a potential approval is likely 5+ years away, assuming successful Phase 1/2/3 development.
- Why 3/10
- No hard dated binary catalyst is scheduled within the next 12 months (the IND was already cleared in July 2026 and the next milestone is clinical-trial enrollment, which has no confirmed date). FT839 is a preclinical/IND-stage program and not the lead asset at Fate Therapeutics, so its share-price impact is limited. The impactScore defaults toward the lower end of the scale.
The next catalyst for FT839 is the initiation of its Phase 1/2 basket study and first patient dosed, which was projected for H2 2026 but has not yet been announced as of November 13, 2026. Watch for a press release on trial initiation; a positive outcome would de-risk the dual-target mechanism but remains a development-stage milestone with no efficacy data for at least 12-18 months. FATE's share price is far more dependent on FT819's Phase 2 RECLAIM-LN lupus nephritis readout than on FT839 progress.
Price Chart
Executive Summary
FT839 is a preclinical, next-generation, off-the-shelf CAR T-cell therapy from Fate Therapeutics (FATE). It is a first-of-kind dual CD19/CD38-targeting, 13-point-genetically-edited iPSC-derived product candidate designed to treat autoimmune diseases and hematological malignancies without conditioning chemotherapy. The FDA cleared its IND application in July 2026, and preclinical data were presented at ACR Convergence 2026 (November 10, 2026). Enrollment in a Phase 1/2 basket study was expected to begin in H2 2026, but no clinical-trial initiation or first-patient-dosed announcement has been made as of mid-November 2026. FT839 is an early-stage program well behind the company's lead asset, FT819 (Phase 2 in lupus nephritis), and has no hard binary catalyst in the next 12 months, limiting its near-term share-price impact for FATE.
How It Works
FT839 is a CAR T-cell therapy made from engineered stem cells (iPSCs) that can be mass-produced and stored, then given to any patient without needing to modify the patient's own cells (off-the-shelf). It is engineered with two targeting molecules (dual CAR) that recognize two proteins on disease-causing immune cells: CD19 and CD38. By hitting both targets, it is designed to eliminate a broader range of harmful immune cells than single-target CAR Ts. It also carries a suite of 13 genetic edits intended to let it work without the harsh chemotherapy normally used to prepare the body for cell therapy.
Trial Status
FT839 received FDA IND clearance in July 2026 for autoimmune diseases. Preclinical data were presented at ACR Convergence 2026 (November 2026). Enrollment in a Phase 1/2 basket study for autoimmune diseases and hematological malignancies was projected to begin H2 2026, but no trial initiation or patient dosing has been announced as of November 13, 2026.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 1/2 basket study and first patient dosed (projected H2 2026, no announcement yet)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
FATE THERAPEUTICS INC 424B5 FATE ·Originating report